- Reuters•2 days ago
Becton Dickinson’s US$24bn takeover of C R Bard in the investment grade medical device sector is the biggest of the year to date as the pipeline kicks back into life after a thin first quarter. Near record stock markets and strong investor demand for debt are fuelling transactions that had been on hold due to volatility created by the US presidential election late last year. “Company valuation multiples are elevated given the stock market, but rather than wait to realize growth, companies are willing to buy it through M&A," said Robert Smock, head of corporate advisory at MUFG.
- Zacks•2 days ago
Becton (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- PR Newswire•2 days ago
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of C. R. Bard, Inc. to Becton, Dickinson and Company for $317 Per Share is Fair to Shareholders - BCR
NEW YORK, April 27, 2017 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased C. R. Bard, Inc. (NYSE: BCR) stock prior to April 23, ...
BDX : Summary for Becton, Dickinson and Company - Yahoo Finance
Becton, Dickinson and Company (BDX)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||186.95 x 100|
|Ask||193.60 x 100|
|Day's Range||181.67 - 187.20|
|52 Week Range||157.60 - 187.20|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||31.12|
|Dividend & Yield||2.92 (1.59%)|
|1y Target Est||N/A|